Lashin, A., Abd El-Ghafar, A., Mahmoud, A., El Shewi, M. (2023). Value of Interleukin 6 in Assessment of the Disease Severity in Patients with COVID-19 Infection without Preexisting Comorbidities. Benha Medical Journal, 40(Annual conference issue), 74-86. doi: 10.21608/bmfj.2023.185224.1738
Amany Helmy Lashin; Amira Osama Abd El-Ghafar; Ahmed Mohamed Mahmoud; Mohammad El Sayed El Shewi. "Value of Interleukin 6 in Assessment of the Disease Severity in Patients with COVID-19 Infection without Preexisting Comorbidities". Benha Medical Journal, 40, Annual conference issue, 2023, 74-86. doi: 10.21608/bmfj.2023.185224.1738
Lashin, A., Abd El-Ghafar, A., Mahmoud, A., El Shewi, M. (2023). 'Value of Interleukin 6 in Assessment of the Disease Severity in Patients with COVID-19 Infection without Preexisting Comorbidities', Benha Medical Journal, 40(Annual conference issue), pp. 74-86. doi: 10.21608/bmfj.2023.185224.1738
Lashin, A., Abd El-Ghafar, A., Mahmoud, A., El Shewi, M. Value of Interleukin 6 in Assessment of the Disease Severity in Patients with COVID-19 Infection without Preexisting Comorbidities. Benha Medical Journal, 2023; 40(Annual conference issue): 74-86. doi: 10.21608/bmfj.2023.185224.1738
Value of Interleukin 6 in Assessment of the Disease Severity in Patients with COVID-19 Infection without Preexisting Comorbidities
1Professor of Hepatology, Gastroenterology, and Infectious diseases, Faculty of Medicine, Benha University
2Lecturer Of Clinical and Chemical Pathology, Faculty of Medicine, Benha University
3Department of Hepatology, Gastroenterology, and Infectious diseases, Faculty of Medicine, Benha University
Abstract
Background: In December of 2019, Wuhan, a new coronavirus-caused pandemic of atypical pneumonia was reported by China. The World Health Organization (WHO) finally designated this coronavirus and its resulting illness as Coronavirus Disease-2019 (COVID-19). Several biomarkers, such as inflammatory markers C-reactive protein (CRP), D-dimer, ferritin, and Interleukin 6 (IL-6), are related to the development of COVID-19. This study purposed to determine value of Interleukin 6 in disease severity assessment of COVID-19 patients without preexisting pathologies. Methods: This observational comparative cross-sectional study was conducted on 100 participants. They were classified into group A included 25 patients classified as mild or moderate cases, group B included 25 patients classified as severe cases, group C included 25 patients classified as critical ill cases and all was positive PCR COVID-19 and group D (Control Group) included 25 control apparently healthy individuals. History has been taken, clinical examination was done and revealed no comorbidities. Serum Interleukin 6 has been measured in all patients using Enzyme-linked immunosorbent assay (ELISA), laboratory investigations and imaging. Results: It revealed that interleukin-6 was a significant predictor for mild to moderate, severe, and critically ill COVID-19 patients, controlling for age and gender using multinomial logistic regression analysis in predicting COVID-19 severity using interleukin-6. Interleukin-6 can distinguish COVID-19 patients from healthy controls with cutoff point > 3 ng/l, it also can distinguish critically ill patients from other patients with cutoff point > 12 ng/l. Conclusion: Interleukin-6 can significantly predict COVID-19 severity (mild to moderate, severe and critically ill) and mortality.
View on SCiNiTO
Top